

Percutaneous Closure of Recurrent Post Infarction Ventricular Septal Rupture Following Patch Repair Using A Newly Designed Custom-Made Device

Eustaquio Maria Onorato¹, Desislava Petrova², and Peter Uzov³

¹Centro Cardiologico Monzino

²Bulgaria Heart and Brain Center, Department of Cardiac Surgery, University Hospital Pleven

³Bulgaria Heart and Brain Center

September 10, 2020

Abstract

Here, we describe a successful catheter-based closure of a recurrent post-infarction VSR using a new custom-made device in a 50-year-old man who had previously undergone emergency surgical repair for acute PIVSR with bovine pericardial patch, coronary artery bypass grafting and mitral valve replacement with mechanical prosthesis.

Introduction

Outcomes of conventional and modified surgical infarct exclusion are acceptable in terms of mid-term survival (1). However, despite a successful initial repair, residual VSR can occur in 5% to 20% of patients (2-4). Infarct extension may lead to patch dehiscence or create a new rupture beyond the margins of the repaired area (5). In view of the high mortality rate associated with reoperation and given the unstable hemodynamic conditions of the patients, interventional closure may be a less invasive alternative.

Case Report

A 50 years-old male without cardiovascular risk factors was admitted with acute inferior myocardial infarction for which he underwent percutaneous coronary intervention (PCI) with implantation of two drug-eluting stents, one in the right coronary artery and the other in the obtuse marginal. After the procedure the patient remained hemodynamically unstable. His transesophageal echocardiography (TEE) showed left ventricular ejection fraction (LVEF) of 40%, moderate mitral regurgitation, inferobasal aneurysm and a large muscular VSR in the infero-posterior septum (Figure 1). He was supported with intra-aortic balloon pump and underwent coronary artery bypass graft, bovine pericardial patch VSR closure and mitral valve replacement. Four days later, he was found to have a residual ventricular rupture (Figure 2) which made him symptomatic again. In view of his clinical conditions (NYHA class III), it was decided to address his recurrent VSR using a catheter-based technique. The patient was consented after the local ethics committee and the local regulatory agency have approved the use of the device. The PIVSR was crossed from left to right ventricle using a retrograde arterial approach (left femoral artery) with a 5F multipurpose catheter and a Terumo wire that was advanced into the inferior vena cava, where it was snared via the right femoral vein establishing an arteriovenous rail (Figure 3). The 18,6 mm residual VSR was closed using a newly designed custom-made occluder (PIVSD device, Occlutech® Holding AG, Switzerland) (Suppl Figures 1-3), not CE marked yet, therefore available for compassionate use only. The requesting physician needs to fill and sign a prescription letter, obtain local Ethics Committee approval and get permission from national authorities.

The waist size of the occluder was 7 mm larger than the VSR size. The device consists of two self-expanding oval-shaped discs (left 36 mm, right 34 mm) composed of a nitinol-wire mesh with “shape-memory” properties joined together by a flexible elliptical waist 10 mm in length and 24 mm in diameter. Thin non-woven polyethylene terephthalate (PET) patches are sutured into both discs and into the inside of the waist to ensure rapid sealing of the defect while optimizing ingrowth of tissue. The procedure was performed under general anesthesia with fluoro-angiography and TTE guidance. The occluder was placed at the appropriate site across the rupture and then released. The device was stable and there was a tiny residual shunt immediately after device implantation. The patient made an uneventful recovery and was discharged after 12 days. At dismissal TTE confirmed stable position of the device with trivial residual left-to-right shunt (Figure 4). At 12-month follow-up the patient remained symptom free. TTE confirmed stable position of the device with no left-to-right shunt, mild left ventricular dysfunction and normal function of the mitral prosthesis.

DISCUSSION

The incidence of residual defect after surgical repair of closure of residual leak after surgery post-MI VSR is noted to be around 10–40% (6). Transcatheter closure as a bail-out or salvage where redo surgery weighs more risk than benefit may provide an attractive and less invasive therapeutic strategy for residual defects (7), contraindications being defect size >35 mm, basal VSR near mitral or aortic valves, and apical VSD without sufficient margins.

This catheter-based procedure can be accomplished using different devices, some of them not specifically designed for this purpose. To date, the majority of studies of transcatheter closure of post-infarction VSR have reported on the use of Amplatzer muscular VSD occluder and recently on the Amplatzer postinfarction muscular VSD device (PIMVSD) (Abbott Vascular, Santa Clara, CA, USA) (8-13). The Amplatzer PIMVSD device is a nitinol construct available in larger sizes than the Amplatzer muscular VSD device (maximum waist diameter, 24 mm versus 18 mm, respectively) with a longer connecting waist (10 mm versus 7 mm) and therefore more suited to larger and complex VSRs. Nevertheless, sometimes there’s the need to implant additional devices with a substantial increase in procedural risks.

A primary transcatheter closure of an acute anterior post-infarction VSD closure has been performed few years ago in an 85-year old female using for the first time the custom-made Occlutech® PIVSD occluder with a successful outcome (14).

The Occlutech® PIVSD occluder is a newly designed device with several advanced features compared to previously existing technology: unique braiding technology, no distal hub, soft and atraumatic flexible oval-shaped discs, special surface treatment reducing the risk of thrombosis. The main advantages of this innovative device in comparison with the Amplatzer post MI occluder are (Supplemental Video): first, a wider range of waist sizes (from 16 mm to 36 mm) with bigger left-sided oval disc and a much greater overlap to be able to catch more substantial healthy myocardium and allow a larger surface area between the ventricular septum and the left-sided disc of the device; second, the 10-mm slit-like elliptical connecting waist has no radial strength to prevent tearing the borders of the patch dehiscence; third, due to its conformability, a waist size of the occluder 8 mm or even 10 mm larger than the rupture size may be used without undermining the margins of the repaired area.

Polyester fabric sutured into both discs and into the inside of the waist requires time to thrombose and endothelialize before being efficient in preventing shunt across the high transventricular pressure gradient. Further minor device modifications such as a denser fabric and covering on the distal left ventricle disc to completely seal off the shunt (“closure at implant”) may be hopefully awaited as well as a dedicated braided and less deformable delivery sheath in order to avoid its kinking.

Conclusions

Percutaneous closure of recurrent PIVSR following patch repair is feasible and may be considered the first-line treatment option.

Keys for success are a good clinical pre-procedural management, the availability of an innovative device and an excellent teamwork.

Acknowledgments

The authors express their appreciation to the staff at Bulmar ML Ltd., Bulgaria for their logistic support. The authors also thank the engineering and marketing staff at Occlutech for technical descriptions of the device and for illustrations.

Conflict of Interest: Eustaquio Maria Onorato is a consultant for Occlutech, manufacturer of the device. The remaining Authors declare no conflict of interest relevant to this publication.

ORCID Eustaquio Maria Onorato <https://orcid.org/0002-6750-5682p>

Author Contribution: EMO contributed to drafting and writing the manuscript; EMO, DP and PU were involved in the care of patient. EMO, PU and DP were involved in the critical revision of the manuscript, the organization of data, the gathering and the image formation. All authors read and approved the final version of the manuscript.

Key Clinical Message

Transcatheter closure as a bail out where surgical closure weighs more risk than benefit may be considered the first-line treatment option whenever hemodynamic condition and morphology are suitable to device closure.

References

1. Topaz O, Taylor AL. Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management. *Am J Med* 1992;93:683–8.
2. Antman EM, Hand M, Armstrong PW et al. 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. *Circulation* 2008;117:296-329.
3. Okamoto Y, Yamamoto K, Asami F et al. Early and midterm outcomes of triple patch technique for postinfarction ventricular septal defects. *Thorac Cardiovasc Surg* 2016;151:1711-1716.
4. Sayfo S, Stepp LO, Ganzel B et al. Management of Recurrent Leaks Following Postinfarction Ventricular Septal Defect Repairs. *J Card Surg* 2012;27:576-580
5. Shah NV, BA, Goldstein JA, Balzer DT et al. Transcatheter Repair of Recurrent Postinfarct Ventricular Septal Defects. *Ann Thorac Surg* 2005;80:1907-1909.
6. Cicekcioglu F, Tutun U, Parlar AI, et al. Residual postmyocardial infarction ventricular septal defect repair through right atrium with right thoracotomy on beating heart technique. *J Card Sur.* 2008;23:580-583.
7. Tang L, Fang Z, Hu X, Tang J, Shen X, Lu X et al. Non-surgical repair of ventricular septal rupture after acute myocardial infarction. *Int J Cardiol.* 2015;185:328-332.
8. Costache VS, Chavanon O, Bouvaist H et al. Early Amplatzer occluder closure of a postinfarct ventricular septal defect as a bridge to surgical procedure. *Interact Cardiovasc Thorac Surg.* 2007;6:503-504.
9. Calvert PA, Cockburn J, Wynne D et al. Percutaneous closure of postinfarction ventricular septal defect: in-hospital outcomes and long-term follow-up of UK experience. *Circulation* 2014;129:2395–2402.
10. Shabestari M, Ghaderi F, Hamedanchi A. Transcatheter Closure of Postinfarction Ventricular Septal Defect: A Case Report and Review of Literature. *J Cardiovasc Thorac Res,* 2015;7:75–77.
11. Barik R. Transcatheter closure of post-myocardial infarction ventricular defect: where are we? *Indian Heart Journal* 2016;68:99–101.
12. Sabiniewicz R, Huczek Z, Zbroński K et al. Percutaneous Closure of Post-Infarction Ventricular Septal Defects — An Over Decade-long Experience. *J Interv Cardiol* 2017;30:63–71.
13. Holzer R, Balzer D, Amin Z et al. Transcatheter closure of postinfarction ventricular septal defects using the new Amplatzer muscular VSD occluder: Results of a U.S. Registry. *Catheter Cardiovasc*

Interv 2004;61:196–201.

14. Fitzsimmons SJ, Macdonald S, Richens T, Vettukattil J. Transcatheter closure of an inferior post infarction ventricular septal defect using a customised device. *Eur Heart J* 2013;34(1):P4349.

Figures legends

Figure 1 . Two-dimensional transesophageal echocardiography (TEE) image showing a large ventricular septal rupture 28 mm in diameter (bracket) located at the infero-posterior septum.

RV: right ventricle; LV: left ventricle; LA: left atrium

Figure 2 . Two-dimensional transthoracic echocardiography (TTE) apical four-chamber (**A,B**) and short-axis color Doppler (**C,D**) views showing post-surgical ventricular residual rupture 18,6 mm in diameter (yellow arrow) with left-to-right shunt (white arrow).

RV: right ventricle; LV: left ventricle

Figure 3 . Fluoro-angiographic procedural steps. **A** : An arteriovenous rail established using a retrograde arterial approach (left femoral artery) with a 5F multipurpose catheter and a Terumo wire that was advanced through the septal rupture into the inferior vena cava, where it was snared via the right femoral vein; **B-D** : the 24 mm PIVSR occluder (black arrows) delivered through the dedicated delivery system (arrowhead) across the septal rupture; the welded ball of the device is secured to the dedicated delivery system (white arrow); **E** : zoom fluoro image showing the device deployment: the welded ball (white long arrow) is no more attached to the dedicated Flex Pusher II delivery system; two radiopaque gold markers are clearly seen on the distal disc. **F** : final LV angiogram showing a stable device position with mild residual left-to-right shunt.

Figure 4 . Two-dimensional transthoracic echocardiography (TTE) at 6-month follow-up. Apical four-chamber (**A**) and short-axis color Doppler (**B-C**) views showing the 24-mm PIVSD occluder in situ (yellow arrow) with trivial residual left-to-right shunt.

RV: right ventricle; LV: left ventricle.

Supplementary Material

Supplemental Figure 1 . Post-Myocardial Infarction Ventricular Septal Defect (PIVSD) Device (Occlutech Holding AG, Switzerland). Available sizes, corresponding to the length of the waist major axis, vary from 16 mm to 36 mm as well as disc diameters (from 28/26 mm to 49/44 mm). Proximal disc diameters are smaller than distal disc ones. The connecting elliptical waist length (h) is 10 mm for all device's sizes. The dedicated delivery system (Flex II Pusher and Pistol Pusher) sizes range from 9-F to 14-F.

Supplemental Figure 2 . The Occlutech PIVSD occluder consists of two self-expanding rounded discs joined together by a 10-mm flexible elliptical waist. The discs and the elliptical waist are composed of a nitinol-wire mesh with “shape-memory” properties. Thin non-woven polyethylene terephthalate patches are sutured into both discs and inside the waist to ensure rapid sealing of the defect while optimizing ingrowth of tissue. Two radiopaque gold markers located on the distal disc are intended to facilitate proper positioning of the device. The size of the device corresponds to the length of the waist major axis (orange line, b: side view). Waist length (h) is 10 mm for all device's sizes. The welded ball is located on the proximal disc (with permission of Occlutech® Holding AG, Switzerland).

Supplemental Figure 3 . On the proximal side of the occluder, the wire braiding ends in a welded ball that serves as an adapter (ball-connector) for the dedicated delivery system (Flex-Pusher II).

Supplemental Video

<https://occlutech.box.com/s/bqarm10gfb3tr4e7mn7789lvt0v0nni4>




Figure 1.




Figure 2.




Figure 3.




Figure 4.